Infinity Pharmaceuticals Company Profile (NASDAQ:INFI)

About Infinity Pharmaceuticals (NASDAQ:INFI)

Infinity Pharmaceuticals logoInfinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:INFI
  • CUSIP: 45665G30
  • Web: www.infi.com
Capitalization:
  • Market Cap: $58.8 million
  • Outstanding Shares: 50,689,000
Average Prices:
  • 50 Day Moving Avg: $1.15
  • 200 Day Moving Avg: $1.83
  • 52 Week Range: $0.84 - $3.84
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.23
  • P/E Growth: -0.01
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.17 per share
  • Price / Book: 0.97
Profitability:
  • EBIDTA: ($55,730,000.00)
  • Return on Equity: -88.08%
  • Return on Assets: -59.20%
Debt:
  • Debt-to-Equity Ratio: 0.35%
  • Current Ratio: 6.29%
  • Quick Ratio: 6.29%
Misc:
  • Average Volume: 773,291 shs.
  • Beta: 2.65
  • Short Ratio: 4
 

Frequently Asked Questions for Infinity Pharmaceuticals (NASDAQ:INFI)

What is Infinity Pharmaceuticals' stock symbol?

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) released its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.12. During the same quarter in the prior year, the firm earned $1.05 earnings per share. View Infinity Pharmaceuticals' Earnings History.

When will Infinity Pharmaceuticals make its next earnings announcement?

Infinity Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Infinity Pharmaceuticals.

Are investors shorting Infinity Pharmaceuticals?

Infinity Pharmaceuticals saw a decline in short interest in the month of August. As of August 31st, there was short interest totalling 908,639 shares, a decline of 22.5% from the August 15th total of 1,172,061 shares. Based on an average daily volume of 658,966 shares, the days-to-cover ratio is currently 1.4 days. Approximately 1.9% of the shares of the stock are short sold.

Who are some of Infinity Pharmaceuticals' key competitors?

Who are Infinity Pharmaceuticals' key executives?

Infinity Pharmaceuticals' management team includes the folowing people:

  • Adelene Q. Perkins, Chairman of the Board, Chief Executive Officer
  • Lawrence E. Bloch M.D. J.D., President, Principal Financial Officer, Principal Accounting Officer
  • William C. Bertrand Jr. Esq., Executive Vice President, General Counsel
  • Melissa Hackel, Vice President - Finance
  • Joseph Pearlberg M.D. Ph.D., Vice President - Clinical Development
  • Norman C. Selby, Lead Outside Independent Director
  • Jeffrey Berkowitz J.D., Independent Director
  • Anthony B. Evnin Ph.D., Independent Director
  • Michael G. Kauffman M.D., Ph.D., Independent Director
  • Ian F. Smith CPA, Independent Director

Who owns Infinity Pharmaceuticals stock?

Infinity Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.17%), Pinnacle Associates Ltd. (2.47%), Platinum Investment Management Ltd. (1.60%), Dimensional Fund Advisors LP (1.29%), Northern Trust Corp (0.75%) and State Street Corp (0.72%). Company insiders that own Infinity Pharmaceuticals stock include Michael C Venuti, Sujay Kango and Value Fund L P Biotechnology. View Institutional Ownership Trends for Infinity Pharmaceuticals.

Who sold Infinity Pharmaceuticals stock? Who is selling Infinity Pharmaceuticals stock?

Infinity Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Acadian Asset Management LLC, Northern Trust Corp, Russell Investments Group Ltd., Vanguard Group Inc., Pinnacle Associates Ltd. and Nationwide Fund Advisors. Company insiders that have sold Infinity Pharmaceuticals stock in the last year include Michael C Venuti and Sujay Kango. View Insider Buying and Selling for Infinity Pharmaceuticals.

Who bought Infinity Pharmaceuticals stock? Who is buying Infinity Pharmaceuticals stock?

Infinity Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Legal & General Group Plc, FMR LLC, Dimensional Fund Advisors LP, LMR Partners LLP, Goldman Sachs Group Inc., Ameriprise Financial Inc. and Zacks Investment Management. View Insider Buying and Selling for Infinity Pharmaceuticals.

How do I buy Infinity Pharmaceuticals stock?

Shares of Infinity Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Infinity Pharmaceuticals' stock price today?

One share of Infinity Pharmaceuticals stock can currently be purchased for approximately $1.14.


MarketBeat Community Rating for Infinity Pharmaceuticals (NASDAQ INFI)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  182 (Vote Outperform)
Underperform Votes:  217 (Vote Underperform)
Total Votes:  399
MarketBeat's community ratings are surveys of what our community members think about Infinity Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Infinity Pharmaceuticals (NASDAQ:INFI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A

Analysts' Ratings History for Infinity Pharmaceuticals (NASDAQ:INFI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/10/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
8/11/2016Morgan StanleyReiterated RatingHold$1.00N/AView Rating Details
8/10/2016FBR & CoReiterated RatingHoldN/AView Rating Details
8/9/2016WedbushReiterated RatingNeutral$1.25 -> $1.00N/AView Rating Details
6/15/2016Jefferies Group LLCDowngradeBuy -> HoldN/AView Rating Details
6/15/2016William BlairDowngradeOutperform -> Market Perform$20.00 -> $2.00N/AView Rating Details
6/15/2016Wells Fargo & CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
6/14/2016Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$12.00 -> $2.00N/AView Rating Details
6/14/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 9/24/2015 forward)

Earnings

Earnings History for Infinity Pharmaceuticals (NASDAQ:INFI)
Earnings by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)
Earnings History by Quarter for Infinity Pharmaceuticals (NASDAQ INFI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.20)N/AView Earnings Details
8/3/2017Q2 2017($0.22)($0.34)ViewListenView Earnings Details
5/9/2017Q1 2017($0.22)($0.21)$19.60 million$0.01 millionViewListenView Earnings Details
3/14/2017Q4 2016($0.57)($0.46)$2.33 millionViewN/AView Earnings Details
11/9/2016Q316($0.84)($0.39)$6.23 millionViewListenView Earnings Details
8/9/2016Q216($0.89)$1.05$13.91 million$9.47 millionViewListenView Earnings Details
5/4/2016Q116($0.82)($0.82)$8.80 million$9.26 millionViewListenView Earnings Details
2/23/2016Q415($0.72)($0.80)$18.26 million$9.10 millionViewListenView Earnings Details
11/5/2015Q315($0.76)$0.84$24.85 million$90.70 millionViewN/AView Earnings Details
8/6/2015Q215($1.00)($0.78)$5.83 million$4.90 millionViewN/AView Earnings Details
5/6/2015Q115($1.69)($1.91)$5.79 million$4.40 millionViewListenView Earnings Details
2/24/2015Q414($0.99)($0.83)$5.61 million$4.36 millionViewListenView Earnings Details
11/6/2014Q314($0.87)$2.03$141.40 million$160.60 millionViewListenView Earnings Details
8/5/2014Q114($0.84)($0.78)ViewN/AView Earnings Details
5/6/2014Q1($0.80)($0.87)ViewListenView Earnings Details
2/25/2014Q413($0.87)($0.68)ViewListenView Earnings Details
11/7/2013($0.75)($0.71)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.62)($0.68)ViewListenView Earnings Details
11/6/2012Q312($0.57)$0.52$13.90 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)
2017 EPS Consensus Estimate: ($0.69)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.23)($0.13)($0.18)
Q2 20172($0.21)($0.12)($0.17)
Q3 20172($0.21)($0.13)($0.17)
Q4 20172($0.21)($0.13)($0.17)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Infinity Pharmaceuticals (NASDAQ:INFI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Infinity Pharmaceuticals (NASDAQ:INFI)
Insider Ownership Percentage: 6.81%
Institutional Ownership Percentage: 67.47%
Insider Trades by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)
Institutional Ownership by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)
Insider Trades by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/17/2017Michael C VenutiDirectorSell6,250$3.48$21,750.00View SEC Filing  
1/3/2017Value Fund L P BiotechnologyMajor ShareholderBuy4,379$1.34$5,867.86View SEC Filing  
12/30/2016Value Fund L P BiotechnologyMajor ShareholderBuy742,401$1.34$994,817.34View SEC Filing  
12/20/2016Value Fund L P BiotechnologyMajor ShareholderBuy654,921$1.31$857,946.51View SEC Filing  
12/13/2016Sujay KangoInsiderSell75,000$1.28$96,000.00View SEC Filing  
12/12/2016Sujay KangoInsiderSell25,009$1.30$32,511.70View SEC Filing  
12/2/2016Value Fund L P BiotechnologyMajor ShareholderBuy201,394$1.19$239,658.86View SEC Filing  
6/25/2015Adelene Q PerkinsCEOSell5,000$10.93$54,650.00View SEC Filing  
6/15/2015Vito J PalombellaInsiderSell4,737$10.97$51,964.89View SEC Filing  
5/27/2015Adelene Q PerkinsCEOSell10,000$12.81$128,100.00View SEC Filing  
5/14/2015Adelene Q PerkinsCEOSell10,000$12.18$121,800.00View SEC Filing  
3/16/2015Adelene Q PerkinsCEOSell20,000$16.00$320,000.00View SEC Filing  
1/29/2015Adelene Q PerkinsCEOSell20,000$14.83$296,600.00View SEC Filing  
12/15/2014Vito J PalombellaInsiderSell4,737$16.32$77,307.84View SEC Filing  
11/26/2014Vito J PalombellaInsiderSell4,736$15.00$71,040.00View SEC Filing  
9/30/2014Anthony B EvninDirectorSell112,451$13.56$1,524,835.56View SEC Filing  
9/3/2014Vito J PalombellaInsiderSell9,472$15.39$145,774.08View SEC Filing  
11/27/2013Anthony B EvninDirectorSell163,864$14.82$2,428,464.48View SEC Filing  
9/13/2013Adelene PerkinsCEOSell45,000$20.72$932,400.00View SEC Filing  
6/20/2013Vito J PalombellaInsiderSell23,150$18.53$428,969.50View SEC Filing  
11/26/2012Christopher M LindblomInsiderSell13,885$25.73$357,261.05View SEC Filing  
9/7/2012Co BeaconMajor ShareholderBuy5,416,565$14.50$78,540,192.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Infinity Pharmaceuticals (NASDAQ:INFI)
Latest Headlines for Infinity Pharmaceuticals (NASDAQ:INFI)
Source:
DateHeadline
americanbankingnews.com logoInfinity Pharmaceuticals, Inc. (INFI) Short Interest Update
www.americanbankingnews.com - September 17 at 1:20 AM
americanbankingnews.com logoFinancial Analysis: Infinity Pharmaceuticals (INFI) vs. RXi Pharmaceuticals Corporation (RXII)
www.americanbankingnews.com - September 10 at 6:26 PM
americanbankingnews.com logoInfinity Pharmaceuticals, Inc. (INFI) Expected to Post Earnings of -$0.21 Per Share
www.americanbankingnews.com - September 5 at 6:14 AM
americanbankingnews.com logoInfinity Pharmaceuticals, Inc. (INFI) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - September 3 at 9:00 AM
americanbankingnews.com logo-$0.21 Earnings Per Share Expected for Infinity Pharmaceuticals, Inc. (INFI) This Quarter
www.americanbankingnews.com - August 17 at 8:26 PM
nasdaq.com logoInfinity (INFI) Q2 Loss Wider than Expected, View Intact - Nasdaq
www.nasdaq.com - August 6 at 4:44 AM
seekingalpha.com logoInfinity Pharmaceuticals' (INFI) CEO Adelene Perkins on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 6 at 4:44 AM
americanbankingnews.com logoInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 5 at 8:22 PM
finance.yahoo.com logoEdited Transcript of INFI earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 8:10 PM
finance.yahoo.com logoInfinity (INFI) Q2 Loss Wider than Expected, View Intact
finance.yahoo.com - August 4 at 8:10 PM
reuters.com logoBRIEF-Infinity Q2 loss per share $0.34
www.reuters.com - August 3 at 8:00 PM
finance.yahoo.com logoInfinity Provides Company Update and Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 8:00 PM
finance.yahoo.com logoInfinity reports 2Q loss
finance.yahoo.com - August 3 at 8:00 PM
americanbankingnews.com logoInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 1 at 12:34 PM
streetinsider.com logoInfinity Pharma (INFI) Amends PI3K-Delta,Gamma Agreement with Takeda
www.streetinsider.com - July 29 at 6:49 PM
streetinsider.com logoInfinity Pharma (INFI) Amends PI3K-Delta,Gamma Agreement with Takeda - StreetInsider.com
www.streetinsider.com - July 28 at 3:41 AM
finance.yahoo.com logoInfinity Amends PI3K-Delta,Gamma Agreement with Takeda Oncology
finance.yahoo.com - July 27 at 10:40 PM
americanbankingnews.com logoFinancial Survey: Celator Pharmaceuticals (CPXX) versus Infinity Pharmaceuticals (INFI)
www.americanbankingnews.com - July 21 at 6:06 PM
finance.yahoo.com logoInfinity Announces the Date of Its Second Quarter 2017 Financial Results Conference Call and Webcast
finance.yahoo.com - July 21 at 3:58 PM
americanbankingnews.com logoInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - July 8 at 11:26 PM
americanbankingnews.com logoInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - July 7 at 12:44 PM
rttnews.com logoCompany Spotlight: Verastem
www.rttnews.com - July 7 at 6:29 AM
americanbankingnews.com logoZacks: Brokerages Expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) to Post -$0.22 Earnings Per Share
www.americanbankingnews.com - July 6 at 10:30 AM
americanbankingnews.com logoValuEngine Upgrades Infinity Pharmaceuticals, Inc. (INFI) to Sell
www.americanbankingnews.com - June 15 at 8:50 PM
prnewswire.com logoInfinity to Participate in Three Upcoming Conferences - PR Newswire (press release)
www.prnewswire.com - June 15 at 6:13 AM
nasdaq.com logoInfinity Pharmaceuticals (INFI) Down 5.3% Since Earnings Report: Can It Rebound? - Nasdaq
www.nasdaq.com - June 14 at 11:23 AM
finance.yahoo.com logoInfinity to Participate in Three Upcoming Conferences
finance.yahoo.com - June 14 at 11:23 AM
finance.yahoo.com logoInfinity Pharmaceuticals (INFI) Down 5.3% Since Earnings Report: Can It Rebound?
finance.yahoo.com - June 13 at 10:55 AM
americanbankingnews.com logoInfinity Pharmaceuticals Inc. (INFI) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 12 at 12:34 PM
americanbankingnews.com logoInfinity Pharmaceuticals Inc. (INFI) Expected to Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - June 12 at 10:24 AM
americanbankingnews.com logoInfinity Pharmaceuticals Inc. (INFI) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - June 4 at 11:14 AM
americanbankingnews.com logoInfinity Pharmaceuticals Inc. (INFI) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 16 at 2:34 PM
americanbankingnews.com logoInfinity Pharmaceuticals Inc. (INFI) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 16 at 1:34 PM
americanbankingnews.com logoInfinity Pharmaceuticals Inc. (INFI) Short Interest Update
www.americanbankingnews.com - May 13 at 7:20 AM
americanbankingnews.com logoQ2 2017 Earnings Forecast for Infinity Pharmaceuticals Inc. (INFI) Issued By William Blair
www.americanbankingnews.com - May 12 at 9:37 AM
businesswire.com logoVerastem Reports First Quarter 2017 Financial Results
www.businesswire.com - May 10 at 6:21 PM
finance.yahoo.com logoEdited Transcript of INFI earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 6:21 PM
prnewswire.com logoInfinity Provides Company Update and Reports First Quarter 2017 ... - PR Newswire (press release)
www.prnewswire.com - May 10 at 1:18 PM
finance.yahoo.com logoInfinity (INFI) Reports Narrower-than-Expected Loss in Q1
finance.yahoo.com - May 10 at 1:18 PM
americanbankingnews.com logoInfinity Pharmaceuticals Inc. (INFI) Posts Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - May 9 at 9:22 PM
marketbeat.com logoInfinity reports 1Q loss
marketbeat.com - May 9 at 5:44 PM
reuters.com logoBRIEF-Infinity reports Q1 loss per share $0.21
www.reuters.com - May 9 at 5:43 PM
finance.yahoo.com logoInfinity Provides Company Update and Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 5:43 PM
finance.yahoo.com logoInvestor Network: Infinity Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 12:23 PM
finance.yahoo.com logoHorizon (HZNP) Falls on Q1 Earnings Miss, Guidance Trimmed
finance.yahoo.com - May 9 at 12:23 PM
finance.yahoo.com logoCatalent (CTLT) Shows Strength: Stock Adds 9.8% in Session
finance.yahoo.com - May 8 at 7:29 AM
seekingalpha.com logoVerastem Boosts Oncologic Drug Portfolio, Fuels Stock Price
seekingalpha.com - May 7 at 6:18 PM
nasdaq.com logoRegeneron (REGN) Q1 Earnings Miss, Revenues Beat Estimates
www.nasdaq.com - May 4 at 6:05 PM
americanbankingnews.com logoInfinity Pharmaceuticals (INFI) Earning Favorable Media Coverage, Study Finds
www.americanbankingnews.com - May 3 at 10:36 AM
americanbankingnews.com logoInfinity Pharmaceuticals (INFI) Earning Somewhat Favorable Media Coverage, Report Shows
www.americanbankingnews.com - April 27 at 11:50 PM

Social

Chart

Infinity Pharmaceuticals (INFI) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by MarketBeat.com Staff